Search

Displaying results 5051 - 5060 of 7540 in total
  1. Drug

    Biricodar

    go.drugbank.com/drugs/DB04851
    Investigational

    The pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).

  2. Drug

    Mongersen

    go.drugbank.com/drugs/DB15019
    Investigational

    Mongersen is under investigation in clinical trial NCT02957474 (A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects

  3. Drug

    CERE-110

    go.drugbank.com/drugs/DB05898
    Investigational

    This drug is developed by Ceregene and currently under phase I of clinical trial.

  4. Drug

    QXL138AM

    go.drugbank.com/drugs/DB18552
    Investigational

    QXL138AM is a masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a. It binds the CD138 protein on the surface of the tumour cells.

    Synonyms: Masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a
  5. Drug

    Bremzalerbart

    go.drugbank.com/drugs/DB19417
    Investigational

    Bremzalerbart is under investigation in clinical trial NCT06602739 (A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen

  6. Drug

    Atisnolerbart

    go.drugbank.com/drugs/DB19418
    Investigational

    Atisnolerbart is under investigation in clinical trial NCT06602739 (A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen

  7. Drug

    Atabecestat

    go.drugbank.com/drugs/DB15307
    Investigational

    Atabecestat is under investigation in clinical trial NCT02211079 (A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9,

  8. Drug

    MN-246

    go.drugbank.com/drugs/DB05981
    Experimental

    MN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.

  9. Drug

    Chlorfenson

    go.drugbank.com/drugs/DB05377
    Experimental

    Chlorfenson is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.

  10. Drug

    PRO-542

    go.drugbank.com/drugs/DB05793
    Investigational

    PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells.